GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dogwood Therapeutics Inc (NAS:DWTX) » Definitions » Price-to-Free-Cash-Flow

DWTX (Dogwood Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Dec. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Dogwood Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-12-12), Dogwood Therapeutics's share price is $2.41. Dogwood Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.83. Hence, Dogwood Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Dogwood Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

DWTX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 36.74
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Dogwood Therapeutics's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.82. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-4.83.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 31.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -11.20% per year.

During the past 6 years, Dogwood Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 31.00% per year. The lowest was -96.60% per year. And the median was -33.70% per year.


Dogwood Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Dogwood Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dogwood Therapeutics Price-to-Free-Cash-Flow Chart

Dogwood Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Dogwood Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dogwood Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Dogwood Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dogwood Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dogwood Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Dogwood Therapeutics's Price-to-Free-Cash-Flow falls into.



Dogwood Therapeutics Price-to-Free-Cash-Flow Calculation

Dogwood Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.41/-4.828
=N/A

Dogwood Therapeutics's Share Price of today is $2.41.
Dogwood Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.83.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Dogwood Therapeutics  (NAS:DWTX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Dogwood Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Dogwood Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Dogwood Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
44 Milton Avenue, Alpharetta, GA, USA, 30009
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Executives
William Pridgen director 44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan director, officer: Chief Executive Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh officer: VP of Finance 44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel director 44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer director 44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald officer: Vice President of Operations 44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau officer: Chief Medical Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch director 44 MILTON AVENUE, ALPHARETTA GA 30009

Dogwood Therapeutics Headlines